Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy

Trial Profile

Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Rocapuldencel-T (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2017 Planned primary completion date changed from 1 Nov 2021 to 5 Sep 2017.
    • 14 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 28 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top